|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 1, January-March 2020
PERSISTENCE AND ADHERENCE TO PARENTERAL FIRST-LINE THERAPIES IN MULTIPLE SCLEROSIS
ACHAQUES RODRÍGUEZ MARTA, LÓPEZ MÉNDEZ PAULA, SÁNCHEZ-RUBIO FERRÁNDEZ JAVIER, IGLESIAS PEINADO IRENE, ALADRO BENITO YOLANDA, MOLINA GARCÍA TERESA
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) with a progressive course. As in other chronic conditions, persistence and adherence play a significant role in achieving optimal therapeutic results. The aim of the present study was to determine the persistence
and adherence of patients with MS to first-line parenteral disease-modifying therapies (DMT) and to assess other factors related to them.
Method: Adherence was treated as a dichotomous variablle (MPR ≥90%) and measured with the medication possession ratio (MPR). Persistence was measured as days on treatment and treated as a dichotomous variablle in the first and second years after treatment initiation. Influence of EDSS, age at initiation and diagnosis, administration route, gender, and phenotype were also studied.
Results: A total of 158 patients were included in the study. The mean time to discontinuation was 1,931 days (95% CI: 1,671-2,190), and 79.1% and 58.9% of patients were persistent in first and second years, respectively. The mean adherence was calculated to be 96.1% (±8.1%), and 86.7% of patients were considered
as adherent to the therapy. Covariates did not show any influence on adherence or persistence.
Conclusion: Patients with MS reported a high persistence and adherence to the first-line parenteral DMT.
ADHERENCE – DISEASE-MODIFYING THERAPIES – MEDICATION POSSESSION RATIO –
MULTIPLE SCLEROSIS – PERSISTENCE